Immunity Inflammation and Disease · 2023 · 13 citations · 44 references
Life SciencesCell BiologyPharmacologyApoptosisCell TherapyChemotherapyAnthracycline CardiotoxicityCardiac BiomarkersOxidative Damage To BiomoleculesOxidative StressReactive Oxygen SpeciesRedox SignalingBone Marrow - Derived CellsBone Marrow Mesenchymal Stem CellsBone Marrow-derived Mesenchymal Stromal CellsExosome-based TherapyGasdermin D-mediated PyroptosisMitochondrial Membrane DamagePhosphatidylinositol 3-Kinase-akt PathwayPi3k-akt Signaling Pathway
OBJECTIVES: Doxorubicin (DOX) can contribute to severe myocardial injury, and bone marrow stromal cells (BMSC)-exosomes (Exos) improves acute myocardial infarction. Hence, this research investigated whether BMSC-Exos alleviated DOX-induced myocardial injury. METHODS: BMSC-derived Exos were isolated and identified, and the optimal concentration of DOX was confirmed. H9C2 cells were treated with DOX and BMSC-Exos or in combination with the protein kinase B (AKT) inhibitor. Reactive oxygen species (ROS) and JC-1 were detected to assess oxidative stress (OS) and mitochondrial membrane damage, respectively. In addition, the expression of pyroptosis-related molecules was measured. The expression of phosphatidylinositol 3 kinase (PI3K)-AKT pathway-related proteins and the phosphorylation and acetylation of forkhead box O1 (Foxo1) in the cell nucleus and cytoplasm were tested. Last, interactions between Foxo1 and gasdermin D (GSDMD) were assessed. RESULTS: BMSC-Exo treatment increased viability and mitochondrial membrane potential and reduced lactic dehydrogenase release and ROS levels in DOX-treated H9C2 cells. Furthermore, the addition of BMSC-Exos suppressed DOX-induced activation and upregulation of NLRP3 and apoptosis-associated speck-like protein containing A CARD (ASC) and in vitro cleavage of caspase-1, GSDMD, interleukin (IL)-1β, and IL-18 proteins. Additionally, BMSC-Exo treatment enhanced the expression of phosphorylated (p)-PI3K, p-AKT, and p-mTOR in DOX-treated H9C2 cells and the levels of phosphorylated Foxo1 in the cytoplasm of DOX-treated H9C2 cells. Foxo1 was enriched in the promoter region of GSDMD. Moreover, the AKT inhibitor API-2 annulled the effects of BMSC-Exos on OS, pyroptosis, and Foxo1 phosphorylation in DOX-treated H9C2 cells. CONCLUSIONS: BMSC-Exos phosphorylated Foxo1 and inactivated Foxo1 transcription via the PI3K-AKT pathway to diminish GSDMD expression, thus restraining DOX-induced pyroptosis and OS of myocardial cells.
44
Gareth R. Willis, Angeles Fernandez‐Gonzalez, Jamie N. Anastas et al. · American Journal of Respiratory and Critical Care Medicine · 2017 · 643 citations · Full text
Tian Li, Wenjiang Cao, Rujing Yue et al. · Journal of Pharmacological Sciences · 2019 · 261 citations · Full text